ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.
Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a new report on Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF), following the release of selected data from its human volunteer LPS challenge trial for lead molecule POLB 001.
Facebook
Twitter
YouTube